United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Two members of Big Pharma are ushering in the "golden age" of biologics in the United States, according to Bernstein analyst Ronny Gal.

Pfizer, Amgen Leading Pharma Into 'Golden Age' of Biosimilars

Gilead Sciences

Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc. (NASDAQ: GILD) announced a deal Friday for GIlead's remdesivir, which has been accorded emergency use authorization by the FDA for treating COVID-19.

Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir

The buddy system will help the pharmaceutical companies quickly ramp up production, even as the coronavirus continues to spread.

Pharma Giant Pfizer Teams With Gilead To Boost Production Of Covid-19 Drug Remdesivir

Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday.

Pfizer agrees to manufacture Gilead's coronavirus drug remdesivir

Shares of Pfizer Inc. PFE, -0.46% gained 1.0% in premarket trading on Friday after it announced that it will help manufacture Gilead Sciences Inc.

Pfizer to help manufacture Gilead's remdesivir

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc.

Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

AstraZeneca

Johnson & Johnson

Merck

Sanofi

Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.

5 Biotech Stocks That Offer Long-Term Growth and Value

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m.

Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020

Many people are putting off vaccinations for diseases they view as less threatening than the coronavirus.

Pfizer, Merck, and Others See a Slowdown in Vaccine Sales, but Anticipate an Autumn Rebound

Both big drugmakers have the potential to make billions from their COVID-19 programs.

Better Coronavirus Stock: Gilead Sciences or Pfizer?

Bristol-Myers

Bristol-Myers Squibb Co. BMY, +0.37% shares rallied in the extended session Wednesday after a federal judge ruled for it and Pfizer Inc.

Bristol-Myers, Pfizer stocks rise on blood-thinner patent win

Alexion Pharma

Royalty Pharma

The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.

5 Large Biotechs and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly improved progression-free survival (PFS), as compared to XALKORI® (crizotinib).

LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

BioNTech SE

GlaxoSmithKline

Inovio Pharmaceuticals

Moderna

Novavax

MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials.

Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad

Dynavax Technologies

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Chevron

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

The six Dogs of the Dow for 2020 had an aggregate decline of 12.7% year-to-date at the end of July. Here's how to trade the stocks now.

How To Trade The 2020 Dogs Of The Dow

Clorox

As the pandemic continues to grow, these four coronavirus stocks are great ways to protect your portfolio for the foreseeable future. 
The post 4 Coronavirus Stocks to Buy as the Pandemic Rages On appeared first on InvestorPlace.

4 Coronavirus Stocks to Buy as the Pandemic Rages On

Which of these cutting-edge biotech companies is leading the coronavirus vaccine race?

Better Coronavirus Stock: Pfizer or Inovio Pharmaceuticals?

Here's why shares of this blue-chip pharma stock are on the verge of a breakout.

3 Reasons to Buy Pfizer

The shares have soared as vaccine candidates progress through human trials. Can the gains continue?

Should You Sell These Coronavirus Vaccine Stocks?

Philip Morris

The US dollar is starting to tailspin lower thanks to a flood of supply.

3 Dividends That Can Survive Powell’s Printing Press

These Coronavirus Vaccine Makers Are Winning the Money Game So Far

CVS Health

Rio Tinto plc Sponsored

Toyota Motor

According to the GuruFocus All-in-One Screener as of July 31, the following guru-held companies have high dividend yields and are trading with low price-earnings ratios.

5 Bargain Stocks With High Dividend Yields

Moderna had a head start in advancing its COVID-19 vaccine into clinical testing. But Pfizer is ahead in some important ways.

Why Pfizer Could Be a Bigger Coronavirus Winner Than Moderna

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, beginning in 2021.

News for Pfizer Stock (PFE)